Bacillus Calmette-Guerin Tokyo172 substrain for superficial bladder cancer: Characterization and antitumor effect

Journal of Urology

Volumn 173, Issue 5, 2005, Pages 1507-1512

  Ikeda, Noriko ^a   Honda, Ikuro ^a   Yano, Ikuya ^a   Koyama, Akira ^a   Toida, Ichiro ^a  

^a Kiyose   (Japan)

Author keywords

Bladder; Bladder neoplasms; Immunotherapy; Mice; Mycobacterium bovis

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ADHERENCE; BCG VACCINATION; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; COLONY FORMING UNIT; CONTROLLED STUDY; DISPERSION; DOSE RESPONSE; DRY WEIGHT; FEMALE; FREEZE DRYING; INTERMETHOD COMPARISON; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR CELL;

EID: 17144412627     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000154354.06892.ba     Document Type: Article

References (16)

1. Milstien, J. B. and Gibson, J. J.: Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ, 68: 93, 1990
2. Brewer, T. F. and Colditz, G. A.: Relationship between bacille Calmette-Guerin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin Infect Dis, 20: 126, 1995
3. Groves, M. J.: Pharmaceutical characterization of. Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine used for the treatment of superficial bladder cancer. J Pharm Sci, 82: 555, 1993
4. Baess, I. and Mansa, B.: Determination of genome size and base ratio on deoxyribonucleic acid from mycobacteria. Acta Pathol Microbiol Scand [B], 86B: 309, 1978
5. Zbar, B. and Rapp, H. J.: Immunotherapy of guinea pig cancer with BCG. Cancer, 34: 1532, 1974
6. Shapiro, A., Ratliff, T. L., Oakley, D. M. and Catalona, W.J.: Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guerin and its correlation with Bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res, 43: 1611, 1983
7. Kelley, D. R., Ratliff, T. L., Catalona, W. J., Shapiro, A., Lage, J. M., Bauer, W. C. et al: Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J Urol, 134: 48, 1985
8. Ratliff, T. L., Palmer, J. O., McGarr, J. A. and Brown, E. J.: Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res, 47: 1762, 1987
9. Ratliff, T. L., Kavoussi, L. R. and Catalona, W. J.: Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol, 139: 410, 1988
10. Ratliff, T. L., Ritchey, J. K., Brandhorst, J. and Hanna, M. G., Jr.: Time-dependent aggregation of reconstituted BCG vaccine. J Urol, 152: 2147, 1994
11. Losa, A., Hurle, R. and Lembo, A.: Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol, 163: 68, 2000
12. Mack, D., Höltl, W., Bassi, P., Brausi, M., Ferrari, P., de Balincourt, C. et al: The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol, 165: 401, 2001
13. Martinez-Pineiro, J. A., Flores, N., Isorna, S., Solsona, E., Sebastian, J. L., Pertusa, C. et al: Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int, 89: 671, 2002
14. Takashi, M., Wakai, K., Ohno, Y., Murase, T. and Miyake, K.: Evaluation of a low-dose intravesical bacillus Calmette-Guerin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol, 27: 723, 1995
15. Irie, A., Uchida, T., Yamashita, H., Matsumoto, K., Satoh, T., Koh, H. et al: Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guerin for superficial bladder cancer recurrence. Int J Urol, 10: 183, 2003
16. Hesseling, A. C., Schaaf, H. S., Hanekom, W. A., Beyers, N., Cotton, M. F., Gie, R. P. et al: Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis, 37: 1226, 2003